Jefferies Raises PT On Amgen, Pricing Pressure Factored IN
Analysts at Jefferies on Friday, March 28, 2014, released a new price target regarding Amgen (NASDAQ: AMGN).
Equity analyst Eun K. Yang at Jefferies led the research and raised their price target from $138.00 to $145.00 per share.
From the 48 cardiologists' surveys taken, Jefferies is increasing its United States and European Union sales estimates for 2017-2020 by 22 to 49 percent. According to Jefferies, this new estimate reflects its broad use in hypercholesterolemia.
Jefferies now estimates sales to be at approximately $1.7 billion in 2019, this is up $0.5 billion from its estimate of $1.2 billion.
The price target issued by Jefferies is based on:
• P/E multiple of ~16x (2015 P/E for big pharma) to our 2015 EPS forecast of $9.26, discounting at 10 percent. • Sum-of-the parts NPV analysis. Risks associated with Amgen include pricing pressure, competition and regulatory delays/failure of evolocumab (AMG-145)
Shares of Amgen are currently trading at $120.55 as of Friday, March 28, 2014.
Latest Ratings for AMGN
|Feb 2017||Bank of America||Upgrades||Neutral||Buy|
|Dec 2016||Oppenheimer||Initiates Coverage On||Outperform|
|Nov 2016||Mizuho||Initiates Coverage On||Buy|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.